You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/67906
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSilva, I. D. C. Guerreiro da-
dc.contributor.authorDias-Netto, E.-
dc.contributor.authorVillanova, F. E.-
dc.contributor.authorYamamoto, L.-
dc.contributor.authorBaracat, E. C.-
dc.contributor.authorLima, G. R.-
dc.contributor.authorGebrim, L. H.-
dc.date.accessioned2014-05-27T11:21:10Z-
dc.date.accessioned2016-10-25T18:19:58Z-
dc.date.available2014-05-27T11:21:10Z-
dc.date.available2016-10-25T18:19:58Z-
dc.date.issued2004-10-11-
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/15491065-
dc.identifier.citationClinical and Experimental Obstetrics and Gynecology, v. 31, n. 3, p. 204-208, 2004.-
dc.identifier.issn0390-6663-
dc.identifier.urihttp://hdl.handle.net/11449/67906-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/67906-
dc.description.abstractTamoxifen was proven to reduce the incidence of breast cancer by 49% in women at increased risk of the disease in the Breast Cancer Prevention Trial. In order to identify potential candidates to explain the preventive effect induced by tamoxifen on breast cancer, normal breast tissue obtained from 42 fibroadenoma patients, randomly assigned to receive placebo or tamoxifen, was analyzed by the reverse Northern blot and RT-PCR techniques. The cDNA fragments used on Northern blot membranes were generated by the Human Cancer Genome Project funded by the Ludwig Institute for Cancer Research and FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo, Brazil). Total RNA was obtained from normal breast tissue from patients with clinical, cytological and ultrasound diagnosis of fibroadenoma. After a 50-day treatment with tamoxifen (10 or 20 mg/day) or placebo, normal breast tissue adjacent to the tumor was collected during lumpectomy with local anesthesia. One differentially expressed gene, Calcium/calmodulin-dependent protein kinase II (CaMKII), was found to be down-regulated during TAM treatment. CaMKII is an ubiquitous serine/threonine protein kinase that has been implicated in the diverse effects of hormones utilizing Ca2+ as a second messenger as well as in c-fos activation. These results indicate that the down-regulation of CaMKII induced by TAM might represent alternative or additional mechanisms of the action of this drug on cell cycle control and response to hormones in normal human breast tissue.en
dc.format.extent204-208-
dc.language.isoeng-
dc.sourceScopus-
dc.subjectBreast Tissue-
dc.subjectCa+2-signalling-
dc.subjectCaMKII-
dc.subjectHuman Cancer Genome Project-
dc.subjectTamoxifen-
dc.subjectDNA fragment-
dc.subjecthormone-
dc.subjectmessenger RNA-
dc.subjectprotein serine threonine kinase-
dc.subjecttamoxifen-
dc.subjectadult-
dc.subjectbreast-
dc.subjectbreast cancer-
dc.subjectbreast fibroadenoma-
dc.subjectcalcium signaling-
dc.subjectcamkII gene-
dc.subjectcell cycle-
dc.subjectclinical article-
dc.subjectclinical trial-
dc.subjectcontrolled clinical trial-
dc.subjectcontrolled study-
dc.subjectcytodiagnosis-
dc.subjectdouble blind procedure-
dc.subjectdown regulation-
dc.subjectdrug mechanism-
dc.subjectechography-
dc.subjectfemale-
dc.subjectgene-
dc.subjectgene activation-
dc.subjectgene expression-
dc.subjectgenome-
dc.subjecthuman-
dc.subjecthuman cancer genome project-
dc.subjecthuman cell-
dc.subjecthuman tissue-
dc.subjectlocal anesthesia-
dc.subjectNorthern blotting-
dc.subjectnucleotide sequence-
dc.subjectoncogene c fos-
dc.subjectpartial mastectomy-
dc.subjectprospective study-
dc.subjectrandomized controlled trial-
dc.subjectreverse transcription polymerase chain reaction-
dc.subjectsecond messenger-
dc.subjectAntineoplastic Agents, Hormonal-
dc.subjectBlotting, Northern-
dc.subjectBreast-
dc.subjectBreast Neoplasms-
dc.subjectCa(2+)-Calmodulin Dependent Protein Kinase-
dc.subjectDouble-Blind Method-
dc.subjectDown-Regulation-
dc.subjectFemale-
dc.subjectFibroadenoma-
dc.subjectHumans-
dc.subjectProspective Studies-
dc.subjectReverse Transcriptase Polymerase Chain Reaction-
dc.subjectRNA, Messenger-
dc.titleTamoxifen down-regulates CaMKII messenger RNA levels in normal human breast tissueen
dc.typeoutro-
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.description.affiliationMolecular Gynecology Laboratory Department of Gynecology Fed. Univ. S. Paulo-Paulista Sch. M.-
dc.description.affiliationNeurosciences Laboratory Psychiatry Institute State University of São Paulo-
dc.description.affiliationMolecular Gynecology Laboratory Gynecology Department Federal University of Sao Paulo, Rua Pedro de Toledo, 781, São Paulo, SP-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofClinical and Experimental Obstetrics and Gynecology-
dc.identifier.scopus2-s2.0-4644350896-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.